| Opinion/The Review

Larger text Larger text Smaller text Smaller text | Order Photo Reprints

Healthy profits

Email Newsletters

Click here to sign up for one of our email newsletters.

Letters home ...

Traveling abroad for personal, educational or professional reasons?

Why not share your impressions — and those of residents of foreign countries about the United States — with Trib readers in 150 words?

The world's a big place. Bring it home with Letters Home.

Contact Colin McNickle (412-320-7836 or

Daily Photo Galleries

By John Stossel
Saturday, Aug. 2, 2014, 9:00 p.m.

I'm the underachiever in my family. My parents also produced Harvard Medical School research director Thomas Stossel. Mom called him the one who had “a real job.”

For years, my brother annoyed me by not embracing the libertarianism that changed my life. It bored him. He was comfortable in his Harvard cocoon.

But then he realized that the anti-capitalist activists who fight with me on my TV show are also the people who make life more difficult for doctors and for patients who want cures.

Lately, the anti-capitalists have become obsessed with “conflict of interest” in science — any trace of corporate money must poison honest medical research.

ObamaCare includes a rule called the Physician Payment Sunshine Act. It orders companies that make medical products to disclose even bagels they serve doctors and anything valued above $10. On my TV show, Tom calls that “the conflict of interest mania ... taking normal competition ... into a witch hunt.”

But doesn't corporate money tempt doctors to push inferior treatments and drugs?

“People cheat for money,” replied Tom. “But evidence that collaborations compromise clinical integrity and patient care is practically nonexistent. A voluminous 2009 Institute of Medicine report on ‘Conflict of Interest in Medical Research' was unable to find evidence of a negative effect on patient outcomes.”

How much good comes from corporate/research collaboration? I assumed that most new drugs and improved medical treatments come because of government-funded research. Tom's reply: “I've lived off government-funded research my whole life. I've panhandled off your tax money. It's important. But the vast predominance of what gets products to patients comes from the private sector.”

His epiphany came when he did work for the biotech company Biogen. Its board included Nobel Prize winners. One helped develop the hepatitis vaccine.

That probably wouldn't happen today, says Tom, because now the stock options the Nobel winner got are forbidden at research institutions like Harvard.

But without government regulation, what prevents greedy doctors and greedy medical device makers or drug companies from colluding?

Market competition. Other scientists will try to replicate dramatic findings and debunk false claims and sloppy scientists. Companies worry about scandal, lawsuits, the FDA and recalls. They can't get rich unless their reputation is good.

The scientific process doesn't work through activists swooping in and pretending to be the guardians of careful research. As Tom writes in a forthcoming book, “Science's credibility derives from its delivery of durable discoveries.” Similarly, sustained profits require products that actually work.

Markets do not automatically taint science. As with every other service the market provides, it is the anti-capitalist attitude that does more harm.

John Stossel is host of “Stossel” on the Fox Business Network. He's the author of “No They Can't: Why Government Fails, but Individuals Succeed.”

Subscribe today! Click here for our subscription offers.



Show commenting policy

Most-Read Stories

  1. Biden, Ryan facing tough decisions
  2. Pirates say goodbye to veteran leaders Burnett, Ramirez
  3. Cole working to become Penguins’ next Martin on defense
  4. Steelers notebook: Starting DEs not leaving the field
  5. Pitt, WR Boyd look to break out against Virginia
  6. Opposing TEs Miller, Gates took differing paths to greatness
  7. Turkish PM says deadly attacks likely were suicide bombings
  8. Plum superintendent says lack of school tip line was ‘oversight’
  9. State woos Kennametal with $1M in incentives to stay in Pa.
  10. Feds aim to bring Chinese military leaders to Pittsburgh for trial
  11. Pittsburgh’s bike sharing service starts off healthy